en
2010 Media releases
| 12/07/10 | Longer follow-up data of PrTasigna* confirms hope for patients with newly diagnosed chronic myeloid leukemia |  |
| 10/28/10 | Novartis Pharmaceuticals Canada Inc. named for seventh time as one of "50 Best Employers in Canada" | |
| 09/28/10 | Mom's breast cancer inspires Novartis employee to join colleagues in sixth annual Toronto-Montreal bicycle "Ride for the Cure" to raise funds for research | |
| 07/08/10 | Novartis receives Health Canada approval of Menveo to prevent meningococcal disease | |
| 06/07/10 | New treatment for major cause of vision loss in diabetes more effective than current standard of care | |
| 03/18/10 | Manitoba government announces reimbursement of Lucentis for people suffering from leading cause of age-related vision loss | |
| 02/05/10 | Tom Rossi named President and CEO of Novartis Pharmaceuticals Canada Inc. | |
| 01/26/10 | Early action against rare cancer reduces relapse risk - Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours | |
| 01/20/10 | New hope: Afinitor® approved in Canada as the first proven treatment for patients with advanced kidney cancer after initial failure of targeted therapy | |
DISCLAIMER FOR ARCHIVES
The information in our Media Release Archives was factually accurate on the date of publication. This information remains on our website for historical purposes only. Novartis Pharmaceuticals Canada Inc. assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon this information as current or accurate after their publication dates.
ABOUT NOVARTIS
On March 7th, 1996 Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis
Our Products
We are a leader in offering medicines to protect health, cure disease and improve well-being.